# US 2023/0129181 A1 · Compounds and their use for the treatment of alpha1-antitrypsin deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0129181 A1
- Document ID: US20230129181A1
- Status: Published application
- Kind: A1
- Application number: 17/839,234
- Filed: 2022-06-13
- Published: 2023-04-27
- Earliest claimed: 2019-12-13
- Assignees: Z Factor Limited
- Applicants: Z Factor Limited
- Inventors: Nigel RAMSDEN; David John FOX; James Andrew HUNTINGTON; James Michael TOMLINSON
- Web page: https://patentgrep.com/patent/US20230129181A1

## CPC

- C07D 213/64: attached in position 2 or 6
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 11/00: Drugs for disorders of the respiratory system
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to specified benzamide compounds of formula (1), and pharmaceutical compositions containing the compounds. The compounds may be inducers of α1-antitrypsin (A1AT), and may be used in the treatment of a disease or disorder such as α1-antitrypsin deficiency (A1AD or AATD).

## Claims

### Claim 1

A compound represented by the structure:
or a pharmaceutically acceptable salt of any one thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is in a crystalline form.

### Claim 3

A pharmaceutical composition comprising a compound represented by the structure:
or a pharmaceutically acceptable salt of any one thereof, and a pharmaceutically r therapeutically acceptable carrier.

### Claim at position 4

-5. (canceled)

### Claim 6

A method of inducing Z A1AT secretion in a subject in need thereof, comprising administering to the subject a compound represented by the structure:
or a pharmaceutically acceptable salt of any one thereof.

### Claim at position 6

-11. (canceled)

### Claim 12 (depends on 1)

The compound of claim 1, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 3)

The pharmaceutical composition of claim 3, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 3)

The pharmaceutical composition of claim 3, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 3)

The pharmaceutical composition of claim 3, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 3)

The pharmaceutical composition of claim 3, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 3)

The pharmaceutical composition of claim 3, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 6)

The method of claim 6, wherein the structure is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 6)

The method of claim 6, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 6)

The method of claim 6, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 6)

The method of claim 6, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.

### Claim 26 (depends on 6)

The method of claim 6, wherein the compound is represented by:
or a pharmaceutically acceptable salt thereof.
